Quality of Life of Patients with Lymphomas at Different Time-Points after High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation

QUALITY OF LIFE , , ,

N.E. Mochkin1, D.A. Fedorenko1, V.Ya. Mel’nichenko1, T.I. Ionova2, T.P. Nikitina1,2, K.A. Kurbatova2, A.A. Novik1

1 N.I. Pirogov National Medical and Surgical Center under the Ministry of Health of the Russian Federation, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203

2 International Quality of Life Research Center, 1 office 152, Artilleriiskaya str., Saint Petersburg, Russian Federation, 191014

For correspondence: N.E. Mochkin, PhD, assistant, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203; Tel: +7(495)603-72-17; e-mail: nickmed@yandex.ru

For citation: Mochkin N.E., Fedorenko D.A., Mel’nichenko V.Ya., Ionova T.I., Nikitina T.P., Kurbatova K.A., Novik A.A. Quality of Life of Patients with Lymphomas at Different Time-Points after HighDose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. Klin. Onkogematol. 2014; 7(4): 577–582 (In Russ.).

 

ABSTRACT

The article presents results of monitoring of quality of life of 103 patients with lymphomas (non-Hodgkin’s lymphomas, n = 36; Hodgkin’s lymphomas, n = 67) at different stages after high-dose chemotherapy with autologic hematopoietic stem cell transplantation (HDC + HSCT). The majority of patients experienced improvement or stabilization of their quality of life 1 year after the HDC + aHSCT. At that, the response associated with the quality of life and clinical response to the treatment did not coincide in all cases. Obtained results confirm the importance of a comprehensive approach to assessment of the efficacy of the treatment and may be use as a principle marker of patient’s recovery at different time points after the transplantation.

Keywords: quality of life, lymphomas, high-dose chemotherapy, autologic hematopoietic stem cell transplantation.

Accepted: September 16, 2014

Read in PDF (RUS)pdficon

REFERENCES

  1. Colpo A., Hochberg E., Chen Y.B. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma. Oncologist. 2012; 17: 80–90.
  2. d’Amore F., Relander T., Lauritzen G.F. et al. High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T-cell lymphoma — final analysis of a large prospective multicenter study (NLGT-01). Blood (ASH Annual Meeting Abstracts). 2011; 118: 331.
  3. Damon L.E., Johnson J.L., Neidzwiecki D. et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J. Clin. Oncol. 2009; 27: 6101–8.
  4. Freidberg J.W. Relapsed/refractory diffuse large B-cell lymphoma. Hematol. Am. Soc. Hematol. Educ. Program. 2011: 498–501.
  5. Geisler C.H., Polstad A., Laurell A. et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008; 112: 2687–93.
  6. Hjermstad M.J., Kaasa S. Quality of life in adult cancer patients treated with bone marrow transplantation — a review of the literature. Eur. J. Cancer. 1995; 31A(2): 163–73.
  7. Kiss T.L., Abdolell M., Jamal N. et al. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogenic bone marrow transplantation. J. Clin. Oncol. 2002; 20(9); 2334–43.
  8. Anderson K.O., Giralt S.A., Mendoza T.R. et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant. 2007; 39(12): 759–66.
  9. Grant M., Ferrel B., Schmidt G.M. et al. Measurement of quality of life in bone marrow transplantation survivors. Qual. Life Res. 1992; 1(6): 375–84.
  10. Новик А.А., Ионова Т.И., Афанасьев Б.В. и др. Результаты аутоло- гичной трансплантации костного мозга/стволовых кроветворных клеток у больных гемобластозами: клиническая эффективность и показатели ка- чества жизни. Вестник Межнационального центра исследования качества жизни. 2011; 17–18: 22–32. [Novik A.A., Ionova T.I., Afanas’ev B.V. et al. Results of autologic bone marrow transplantation/hematopoietic stem cells transplantation in patients with hemoblastoses: clinical efficacy and parameters of quality of life. Vestnik Mezhnatsional’nogo tsentra issledovaniya kachestva zhizni. 2011; 17–18: 22–32. (In Russ.)]
  11. Rock E.P., Kennedy D.L., Furness M.H. et al. Patient-reported outcomes supporting anticancer product approvals. J. Clin. Oncol. 2007; 25: 5094–9.
  12. Fairclough D. Patient-reported outcomes as endpoints in medical research. Sta. Meth. Med. Res. 2004; 13: 115–38.
  13. Gondek K., Sagnier P., Gichrist K., Wooley J. Current status of patientreported outcomes in industry-sponsored oncology clinical trials and product labels. J. Clin. Oncol. 2007; 25(32): 5087–93.
  14. Steven B. Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making. J. Clin. Oncol. 2007; 25(32): 5049–50.
  15. Watkins B. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the national cancer institute-sponsored clinical trials networks. J. Clin. Oncol. 2007; 25(32): 5051–7.
  16. Molassiotis A., Van der Akker O., Milligan D. et al. Quality of life in longterm survivors of marrow transplantation: Comparison with a matched group receiving maintenance chemotherapy. Bone Marrow Transplant. 1996; 17: 249–58.
  17. Руководство по исследованию качества жизни в медицине, 3-е изд., перераб. и доп. Под ред. Ю.Л. Шевченко. М.: Изд-во РАЕН, 2012. [Shevchenko Yu.L., ed. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine (Guidelines for evaluation of the quality of life in medicine). 3rd revised edition. Moscow: RAEN Publ.; 2012.]
  18. Neitzert C.S., Ritvo P., Dancey J. et al. The psychosocial impact of bone marrow transplantation: A review of the literature. Bone Marrow Transplant. 1998; 22: 409–22.
  19. Wingard J.R. Quality of life following bone marrow transplantation. Curr. Opin. Oncol. 1998; 10: 108–11.
  20. Chao N.J., Tierney D.K., Bloom J.R. et al. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood. 1992; 80: 825–30.
  21. Cohen M.Z., Mendoza T., Neumann J. et al. Longitudinal assessment of symptoms and quality of life: Differences by ablative and nonablative blood and marrow transplantation. J. Clin. Oncol. 2004; 22(15S): 6630.
  22. Ganz P., Gotay C. Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials; Lessons Learned and Future Directions. J. Clin. Oncol. 2007; 25(32): 5063–9.
  23. Novik A., Salek S., Ionova T. Patient-reported outcomes in hematology. Guidelines. EHA SWG Quality of Life and Symptoms. Litoprint. Genoa, 2012.
  24. Hays R.D., Sherbourne C.D., Mazel R.M. User’s Manual for Medical Outcomes Study (MOS) Core measures of health-related quality of life. RAND Corporation, MR-162-RC. Available at www.rand.org.
  25. Новик А.А., Ионова Т.И. Исследование качества жизни в медицине: Учебное пособие для вузов. Под ред. Ю.Л. Шевченко. М.: ГЭОТАР-Медиа, 2004. [Novik A.A., Ionova T.I. Issledovanie kachestva zhizni v meditsine (Evaluation of the quality of life in medicine). Textbook for institutes of higher education. Shevchenko Yu.L., ed. Moscow: GEOTAR-Media Publ.; 2004.]
  26. Новик А.А., Ионова Т.И. Интегральный показатель качества жизни — новая категория в концепции исследования качества жизни. Вестник Межнационального центра исследования качества жизни. 2006; 7–8: 7–8. [Novik A.A., Ionova T.I. Integral assessment of quality of life is a new category in the concept of evaluation of quality of life. Vestnik Mezhnatsional’nogo tsentra issledovaniya kachestva zhizni. 2006; 7–8: 7–8. (In Russ.)]